Macrophage LXRα gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR/mice

Gene Therapy

Volumn 18, Issue 8, 2011, Pages 835-841

  Li, G ^a   Biju, K C ^a   Xu, X ^a   Zhou, Q ^a   Chen, C ^a   Valente, A J ^a   He, W ^a   Reddick, R L ^a   Freeman, G L ^a   Ahuja, S S ^a   Clark, R A ^a   Li, S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; LXR ; macrophage; stem cell gene therapy; triglyceride

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN E; CD11B ANTIGEN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 6; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; GENE TARGETING; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPERTRIGLYCERIDEMIA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; STEREOISOMERISM; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BONE MARROW TRANSPLANTATION; FEMALE; GENE THERAPY; HYPERTRIGLYCERIDEMIA; INTERLEUKIN-6; LENTIVIRUS; MACROPHAGES; MICE; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, LDL; TRANSDUCTION, GENETIC; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 80051781844     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.29     Document Type: Article

References (35)

1. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-614. (Pubitemid 43326865)
2. Scott J. The liver X receptor and atherosclerosis. N Engl J Med 2007; 357: 2195-2197.
3. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 2001; 107: 565-573. (Pubitemid 32206188)
4. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-731. (Pubitemid 26360651)
5. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002; 99: 11896-11901. (Pubitemid 34994495)
6. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-7609. (Pubitemid 34568738)
7. Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005; 25: 135-142. (Pubitemid 40054266)
8. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002; 277: 11019-11025. (Pubitemid 34952859)
9. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-2838.
10. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-516.
11. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8268.
12. Smith JD. An A+ for macrophages in reducing atherosclerosis? Arterioscler Thromb Vasc Biol 2001; 21: 1710-1711. (Pubitemid 34219771)
13. He W, Qiang M, Ma W, Valente AJ, Quinones MP, Wang W et al. Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther 2006; 17: 949-959. (Pubitemid 46076755)
14. Linton MF, Babaev VR, Gleaves LA, Fazio S. A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. J Biol Chem 1999; 274: 19204-19210.
15. Watanabe Y, Tanaka T, Uchiyama Y, Takeno T, Izumi A, Yamashita H et al. Establishment of a monoclonal antibody for human LXRalpha: detection of LXRalpha protein expression in human macrophages. Nucl Recept 2003; 1: 1.
16. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001; 98: 507-512. (Pubitemid 32105072)
17. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000; 11: 243-251. (Pubitemid 30336021)
18. Beyea MM, Heslop CL, Sawyez CG, Edwards JY, Markle JG, Hegele RA et al. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J Biol Chem 2007; 282: 5207-5216. (Pubitemid 47093759)
19. Ginsberg H. New perspectives on atherogenesis: role of ABNORMAL triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 2137-2142. (Pubitemid 35192822)
20. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-219. (Pubitemid 36227724)
21. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 2137-2142. (Pubitemid 39482442)
22. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999; 19: 2364-2367. (Pubitemid 29477837)
23. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007; 48: 751-762.
24. Tontonoz P, Mangelsdorf DJ. Liver x receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-993. (Pubitemid 36683707)
25. Teupser D, Kretzschmar D, Tennert C, Burkhardt R, Wilfert W, Fengler D et al. Effect of macrophage overexpression of murine liver X receptor-{alpha} (LXR-{alpha}) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 2009-2015.
26. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000; 97: 12097-12102.
27. Rott D, Zhu J, Zhou YF, Burnett MS, Zalles-Ganley A, Epstein SE. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 2003; 170: 223-228. (Pubitemid 37377793)
28. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005; 180: 11-17.
29. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007; 318: 1296-1299. (Pubitemid 350172893)
30. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920-1923.
31. Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, Morici LA et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004; 21: 877-889. (Pubitemid 39626676)
32. Qiao M, Kisgati M, Cholewa JM, Zhu W, Smart EJ, Sulistio MS et al. Increased expression of glutathione reductase in macrophages decreases atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1375-1382. (Pubitemid 46809428)
33. Biju KC, Zhou Q, Li G, Imam SZ, Roberts JL, Morgan WW et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther 2010; 18: 1536-1544.
34. Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Therapy 2002; 9: 1155-1162. (Pubitemid 34993938)
35. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368-2371. (Pubitemid 33140563)